Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1187014/full |
| _version_ | 1797847182709096448 |
|---|---|
| author | Rosalba D’Alessandro Maria Grazia Refolo Annalisa Schirizzi Giampiero De Leonardis Rossella Donghia Vito Guerra Gianluigi Giannelli Ivan Roberto Lolli Maria Maddalena Laterza Ferdinando De Vita Caterina Messa Claudio Lotesoriere |
| author_facet | Rosalba D’Alessandro Maria Grazia Refolo Annalisa Schirizzi Giampiero De Leonardis Rossella Donghia Vito Guerra Gianluigi Giannelli Ivan Roberto Lolli Maria Maddalena Laterza Ferdinando De Vita Caterina Messa Claudio Lotesoriere |
| author_sort | Rosalba D’Alessandro |
| collection | DOAJ |
| first_indexed | 2024-04-09T18:07:10Z |
| format | Article |
| id | doaj.art-bdbbe366da69448e959e5d710e22e3fb |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T18:07:10Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-bdbbe366da69448e959e5d710e22e3fb2023-04-14T05:40:32ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-04-011310.3389/fonc.2023.11870141187014Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective studyRosalba D’Alessandro0Maria Grazia Refolo1Annalisa Schirizzi2Giampiero De Leonardis3Rossella Donghia4Vito Guerra5Gianluigi Giannelli6Ivan Roberto Lolli7Maria Maddalena Laterza8Ferdinando De Vita9Caterina Messa10Claudio Lotesoriere11Laboratory of Experimental Oncology, National Institute of Gastroenterology - IRCCS “Saverio de Bellis”, Castellana Grotte, ItalyLaboratory of Experimental Oncology, National Institute of Gastroenterology - IRCCS “Saverio de Bellis”, Castellana Grotte, ItalyLaboratory of Experimental Oncology, National Institute of Gastroenterology - IRCCS “Saverio de Bellis”, Castellana Grotte, ItalyLaboratory of Experimental Oncology, National Institute of Gastroenterology - IRCCS “Saverio de Bellis”, Castellana Grotte, ItalyData Science Unit, National Institute of Gastroenterology - IRCCS “Saverio de Bellis”, Castellana Grotte, ItalyData Science Unit, National Institute of Gastroenterology - IRCCS “Saverio de Bellis”, Castellana Grotte, ItalyScientific Direction, National Institute of Gastroenterology - IRCCS “Saverio de Bellis”, Castellana Grotte, ItalyMedical Oncology Unit, National Institute of Gastroenterology - IRCCS “Saverio de Bellis”, Castellana Grotte, ItalyComplex Operating Unit Oncologia, Local Health Authority Napoli 2 Nord, P.O. “S.M. delle Grazie”, Naples, ItalyDivision of Medical Oncology, Department of Precision Medicine, School of Medicine, University of Study of Campania “Luigi Vanvitelli”, Naples, ItalyLaboratory of Experimental Oncology, National Institute of Gastroenterology - IRCCS “Saverio de Bellis”, Castellana Grotte, ItalyMedical Oncology Unit, National Institute of Gastroenterology - IRCCS “Saverio de Bellis”, Castellana Grotte, Italyhttps://www.frontiersin.org/articles/10.3389/fonc.2023.1187014/fullangiogenesisgastric cancertarget therapybiomarkerscancer progression |
| spellingShingle | Rosalba D’Alessandro Maria Grazia Refolo Annalisa Schirizzi Giampiero De Leonardis Rossella Donghia Vito Guerra Gianluigi Giannelli Ivan Roberto Lolli Maria Maddalena Laterza Ferdinando De Vita Caterina Messa Claudio Lotesoriere Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study Frontiers in Oncology angiogenesis gastric cancer target therapy biomarkers cancer progression |
| title | Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study |
| title_full | Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study |
| title_fullStr | Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study |
| title_full_unstemmed | Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study |
| title_short | Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study |
| title_sort | corrigendum variations in circulating levels of angiopoietin 2 over time are predictive of ramucirumab paclitaxel therapy outcome in advanced gastric cancer results of prospective study |
| topic | angiogenesis gastric cancer target therapy biomarkers cancer progression |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1187014/full |
| work_keys_str_mv | AT rosalbadalessandro corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy AT mariagraziarefolo corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy AT annalisaschirizzi corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy AT giampierodeleonardis corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy AT rosselladonghia corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy AT vitoguerra corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy AT gianluigigiannelli corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy AT ivanrobertololli corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy AT mariamaddalenalaterza corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy AT ferdinandodevita corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy AT caterinamessa corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy AT claudiolotesoriere corrigendumvariationsincirculatinglevelsofangiopoietin2overtimearepredictiveoframucirumabpaclitaxeltherapyoutcomeinadvancedgastriccancerresultsofprospectivestudy |